Mon, Feb 12, 2024
Aurobindo Pharma's consolidated profit after tax (PAT) skyrocketed by 91 per cent to Rs. 940 crore against Rs 491 crore Year-on-Year (YoY), compared to Zee Business research estimates of Rs. 904 crore. Its revenue from operations for the December quarter was up by 15 per cent to Rs 7352 crore in Q3 compared to 6407 crore YoY, below research estimates of Rs 7421 crore.
More >
Thu, Jan 12, 2017
Piyush Nahar and Anurag Mantry analysts of Jefferies said, “We expect another muted quarter for the pharma sector led by weakness in US business. USFDA inspections and pricing in US market will continue to dominate the results. Recent comments from global peers have indicated that pricing scenario will likely remain unchanged in 2017.”
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
